Key Events This Week
28 Sep: Stock opens at Rs.5.35, down 1.29% amid broader market weakness
30 Sep: Hits lower circuit at Rs.5.44 due to intense selling pressure
1 Oct: Surges to upper circuit at Rs.5.71 on strong buying interest
2 Oct: Week closes at Rs.5.61, up 3.51% for the week
28 September: Market Weakness Sets the Tone
Vivimed Labs opened the week at Rs.5.35 on 28 September 2026, down 1.29% from the previous close of Rs.5.42. This decline occurred amid a broader market sell-off, with the Sensex falling 1.60% to 34,788.97. The stock’s volume was moderate at 3,452 shares, reflecting cautious investor sentiment. The pharmaceutical sector was also under pressure, contributing to the subdued start for Vivimed Labs.
30 September: Lower Circuit Hit Amid Heavy Selling Pressure
On 30 September, Vivimed Labs faced intense selling pressure, hitting its lower circuit price limit at Rs.5.44, a 1.98% drop from the previous day’s close. The stock’s trading was frozen at this level, indicating panic selling and a lack of buyers willing to absorb the supply. The total traded volume was extremely low at just 8,910 shares, with delivery volume plunging 87.16% compared to the five-day average, signalling a sharp liquidity contraction.
This underperformance was stark against the Pharmaceuticals & Drugs sector, which declined only 0.63%, and the Sensex, which was nearly flat, down 0.09%. Technical indicators showed the stock trading below all key moving averages, confirming sustained bearish momentum. The market capitalisation stood at Rs.45.11 crore, underscoring its micro-cap status and vulnerability to volatility.
Investor sentiment appeared fragile, with the strong sell rating (Mojo Score 17.0, upgraded to Strong Sell on 12 May 2026) reflecting deteriorating fundamentals and technical outlook. The lower circuit event highlighted the risk of further downside if selling pressure persists.
Our current monthly pick, this Mid Cap from Automobile Two & Three Wheelers, survived rigorous evaluation against dozens of contenders. See why experts are backing this one!
- - Rigorous evaluation cleared
- - Expert-backed selection
- - Mid Cap conviction pick
1 October: Sharp Rebound to Upper Circuit on Strong Buying
In a dramatic reversal, Vivimed Labs surged to its upper circuit limit at Rs.5.71 on 1 October 2026, gaining 4.96% in a single session. This rally was driven by robust buying interest, pushing the stock above its 5-day moving average, although it remained below longer-term averages. The total traded volume increased to 6,905 shares, with delivery volume on 30 September having surged 252.59% compared to the five-day average, signalling renewed investor participation.
This performance contrasted sharply with the Pharmaceuticals & Drugs sector, which declined 0.28%, and the Sensex, which slipped 0.24%. The upper circuit triggered a regulatory trading halt, reflecting significant unfilled demand and a sudden shift in market sentiment.
Despite this short-term bullish momentum, the stock’s Strong Sell Mojo Grade and micro-cap status suggest caution. The rally may be driven by speculative interest rather than fundamental improvements, and the stock remains vulnerable to volatility given its technical positioning and sector headwinds.
Vivimed Labs Ltd or something better? Our SwitchER feature analyzes this micro-cap stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
2 October: Week Closes on a Positive Note
Trading data for 2 October was unavailable, but the week closed with Vivimed Labs at Rs.5.61, representing a 3.51% gain from the previous Friday’s close of Rs.5.42. This outperformance against the Sensex’s 3.20% decline highlights the stock’s volatile but ultimately positive weekly trajectory. The stock’s micro-cap nature and recent circuit hits underscore the importance of monitoring liquidity and volatility in coming sessions.
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-09-28 | Rs.5.35 | -1.29% | 34,788.97 | -1.60% |
| 2026-09-29 | Rs.5.45 | +1.87% | 34,621.52 | -0.48% |
| 2026-09-30 | Rs.5.35 | -1.83% | 34,564.37 | -0.17% |
| 2026-10-01 | Rs.5.61 | +4.86% | 34,221.41 | -0.99% |
Key Takeaways
The week for Vivimed Labs was characterised by extreme volatility, with the stock hitting both lower and upper circuit limits within three trading sessions. This reflects a highly speculative trading environment typical of micro-cap stocks with limited liquidity.
Despite the strong rebound on 1 October, the stock remains below most longer-term moving averages, and the Strong Sell Mojo Grade signals underlying fundamental weaknesses. The surge in delivery volumes ahead of the rally suggests genuine investor interest, but the sustainability of this momentum is uncertain.
The stock’s outperformance relative to the Sensex’s decline is notable, but investors should remain cautious given the sector’s regulatory challenges and the company’s micro-cap status. The sharp swings in price and volume highlight the elevated risk and potential for further volatility.
Conclusion
Vivimed Labs Ltd’s week ending 2 October 2026 was marked by significant price swings, with a 3.51% weekly gain contrasting a 3.20% drop in the Sensex. The stock’s journey from a lower circuit hit to an upper circuit surge underscores the fragile and volatile nature of trading in this micro-cap pharmaceutical company. While the recent buying interest is encouraging, the prevailing Strong Sell rating and technical weaknesses counsel prudence. Market participants should closely monitor liquidity, volume trends, and sector developments before making further commitments.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
